StockDiagnostics.com Secures $1.3 Million Advertising and Marketing Budget

Tuesday December 10, 2:37 pm ET

SARASOTA, Fla.--(BUSINESS WIRE)--Dec. 10, 2002-- StockDiagnostics.com Plans to Kick Off Marketing and Advertising Campaign by End of Year;

Website Diagnoses "Sick" Stocks for Investors

StockDiagnostics.com, an independent stock research firm that diagnoses "sick" and "healthy" stocks by tracking operational cashflow per share results as they compare to reported earnings per share results, today announced it has secured $1.3 million in funding to launch an aggressive advertising and marketing campaign.

The company expects to kickoff its campaign by the end of this year.

StockDiagnostics.com has seen its revenues increase more than 100 percent in the past two months and is finding its visitor to subscriber conversion rates running 10 times higher than the national average.

StockDiagnostics.com (http://www.stockdiagnostics.com) was initially available to investors from May through November as a free site, providing valuable, objective information on more than 7,000 publicly-traded companies. The company has an automated system that has issued OPS (operational cashflow per share) downgrades and OPS upgrades for 3,411 companies since May 1, 2002.

StockDiagnostics.com screens public companies' filings with the SEC for more than 1800 different data points and then culls through that data to provide at-a-glance information that is completely objective and quantitative. In December, the site became subscriber-based at a cost of $29.95 per month. StockDiagnostics.com reports that its subscriber base has more than doubled since the move to a proprietary subscription-only site.

During the past six months, StockDiagnostics.com has built an impressive track record of early diagnosis of "sick" companies before these companies reported their problems publicly. In addition to its diagnosis of D & K Healthcare, Concord EFS, Patterson Dental, Reliant Resources, Inc. and Adelphia Communications, the company was the first to publicly warn investors on Sears credit card receivables problems before they were disclosed by Sears management (see http://www.StockDiagnostics.com for chronology of events involving Sears and StockDiagnostics.com).

StockDiagnostics.com believes that the tracking of OPS (operational cashflow per share) is important to investors, as OPS, which is a proprietary financial analysis metric created by the company, can help address the issues and concerns that have come about as the credibility of EPS has eroded. Where accounting gimmickry can allow companies to report "cashless" earnings per share, OPS is difficult to manipulate and for that reason can provide investors with a true and clear picture of the health of a given company.

StockDiagnostics.com also provides investors with a special diagnosis of EPS Syndrome(TM), a condition that can only be diagnosed once the first symptom appears: a company reports record earnings yet at the same time demonstrates negative OPS. That alone will trigger the StockDiagnostics.com proprietary algorithms to screen for other anomalies that, if found, result in the diagnosis of The EPS Syndrome. Companies such as Enron, Sunbeam, and Suprema Specialties are only three of many that are classic cases of EPS Syndrome. Record earnings announcements can be insidious as they can lull investors into holding or making investments in companies that without The EPS Syndrome diagnosis would otherwise appear to be doing very well. Wall Street research has, in the past, added to this false sense of security, since many diagnosed companies may carry multiple analysts' "strong buy" and "buy" ratings.

Information on StockDiagnostics.com can be obtained at the website: http://www.stockdiagnostics.com.

News media who wish to checkout the site are invited to contact Bev Jedynak, at Martin E. Janis & Company, Inc., 312/943-1100 ext. 12; b.jedynak-janispr@att.net for a username and password.